{"id":"W2914616519","doi":"10.1016/j.ophtha.2019.01.013","title":"Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease","year":2019,"lang":"en","type":"article","venue":"Ophthalmology","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University; Novartis (Canada); McGill University; University of Calgary; University of Alberta; University of Toronto; Centre Intégré de Santé et de Services Sociaux du Bas-Saint-Laurent; Sunnybrook Health Science Centre","funders":"Bayer Canada; Allergan; Novartis Pharmaceuticals Canada; Novartis; Roche; Bayer","keywords":"Medicine; Ranibizumab; Macular degeneration; Visual acuity; Choroidal neovascularization; Regimen; Dosing; Ophthalmology; Randomized controlled trial; Confidence interval; Diabetic retinopathy; Bevacizumab; Surgery; Internal medicine; Chemotherapy; Diabetes mellitus","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00005533642,0.0002254232,0.0005779135,0.0004053482,0.00004339891,0.00001468212,0.00006062151,0.00009397576,0.001003017],"category_scores_gemma":[0.00001575611,0.0001496714,0.0001548732,0.0005682412,0.00007707599,0.00005014474,0.00001517997,0.0001149167,0.0000455486],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001756257,"about_ca_system_score_gemma":0.0002331155,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0324414,"about_ca_topic_score_gemma":0.001588396,"domain_scores_codex":[0.9986345,0.00008711919,0.000202581,0.0004785994,0.0002266789,0.0003705461],"domain_scores_gemma":[0.9988461,0.00002182661,0.00006238249,0.0004336849,0.00005677747,0.0005791918],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03912602,0.0004626501,0.9470633,0.00002405837,0.001650582,0.01127998,0.00003160088,0.00006677256,6.335418e-7,0.00002990949,0.000004306107,0.0002601764],"study_design_scores_gemma":[0.06746798,0.002559065,0.9262429,0.00003773412,0.003249561,0.0001092729,0.00001491747,0.00009472972,7.359958e-7,0.00003833052,0.00002661946,0.0001581075],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951171,0.0002507984,6.063773e-7,0.0001432535,0.00003027183,0.001166473,0.00003685469,0.00001108773,0.003243584],"genre_scores_gemma":[0.9973075,0.000006873945,0.00005387501,0.00004533096,0.00001078766,0.00004405267,0.0006042799,0.00002722527,0.001900066],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.030853,"threshold_uncertainty_score":0.9999102,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.004252280861809472,"score_gpt":0.2261937874485722,"score_spread":0.2219415065867627,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}